COVID-19 vaccines-related adverse events and associated factors reported among adult Egyptians 10.55131/jphd/2023/210104
Article Sidebar
Main Article Content
Abstract
COVID-19 vaccine recipients are more likely to experience post-vaccination adverse events, which are considered the source of concerns about vaccine safety. This study aims to describe the utilization of COVID-19 vaccines and the associated adverse events and their possible predictors among adult Egyptians. An online cross-sectional study was designed to collect data through a Google Form questionnaire in November 2021. Adults who received at least one dose of the COVID-19 vaccine were asked to report their experience with vaccination and associated adverse events. A total of 853 participants were included in the study after receiving Sinopharm/Sinovac (63%), AstraZeneca (27%), Pfizer-BioNTech (4.8%), and other vaccines (5.2%). Around 50% of participants thought that COVID-19 vaccines were safe, 30.8% advised others with vaccination, and 68.3% reported post-vaccination adverse events. The most commonly encountered adverse symptoms were injection site pain (82.5%), fatigue (67.4%), flu-like symptoms (59.6%), and bone and muscle pains (59.6%). Most adverse events were less likely reported by Sinopharm/Sinovac recipients than recipients of other vaccines. The significant predictors for reporting adverse events were female gender, the first dose of vaccination, and vaccine type (AstraZeneca versus Sinopharm/Sinovac) with multivariable-adjusted OR (95% CI) = 1.85 (1.34-2.54); 2.01 (1.24–3.25), and 3.86 (2.54–5.86). Findings revealed that adverse events of COVID-19 vaccines are common. Sinopharm/Sinovac recipients were reported to have lesser adverse events than other recipients. However, serious reactions were rare which ensures the safety of all vaccine types among the adult Egyptian population.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
World Health Organization. Weekly epidemiological update on COVID-19 - 22 June 2022, edition 97 [Internet]. [Cited 2022 Jun 28]. Avaiable from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---22-june-2022
World Health Organization. Egypt: WHO Coronavirus Disease (COVID-19) Dashboard with Vaccination Data 2022 [Internet]. [Cited 2022 June 28]. Avaiable from: https://covid19.who.int/ region/emro/country/eg
Kashte S, Gulbake A, El-Amin III SF, Gupta A. COVID-19 vaccines: rapid development, implications, challenges and future prospects. Hum Cell. 2021;34(3):711-33. doi: https://doi.org/ 10.1007/s13577-021-00512-4
Ministry of Health and population E. Five different vaccines against COVID-19 are available in Egypt’s vaccination centers [Internet]. 2021. [Cited 2022 June 15]. Avaiable from: https://www. egypttoday.com/Article/1/106929/Five-different-vaccines-against-COVID-19-are-available-in-Egypt%E2%80%99s
De Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study. Lancet. 2020; 26;396(10255):898-908. doi: https://doi.org/10.1016/S0140-6736(20)31558-0
Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem. 2021; 36(4):427-39. doi: https://doi.org/ 10.1007/s12291-021-00968-z
Fiolet T, Kherabi Y, MacDonald C-J, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28:202-21. doi: https://doi.org/10.1016/j.cmi.2021. 10.005
Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S, et al. Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines. 2021;9(6):674. doi: https://doi.org/10.3390/ vaccines9060674
Biswas M, Alzubaidi MS, Shah U, Abd-Alrazaq AA, Shah Z. A scoping review to find out worldwide COVID-19 vaccine hesitancy and its underlying determinants. Vaccines. 2021;9(11): 1243. doi: https://doi.org/10.3390/ vaccines9111243
Elsayed M, El-Abasiri RA, Dardeer KT, Kamal MA, Htay MNN, Abler B, et al. Factors influencing decision making regarding the acceptance of the COVID-19 vaccination in Egypt: A cross-sectional study in an urban, well-educated sample. Vaccines. 2022; 10(1):20. doi: https://doi.org/10.3390/ vaccines10010020
Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021;325(21):2201-2. doi: https://doi.org/10.1001/jama.2021.5374
Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al. Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. Vaccines. 2021;9(6):556. doi: https://doi.org/ 10.3390/vaccines9060556
Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F.The how’s and what’s of vaccine reactogenicity. NPJ Vaccines 2019;4(1):1-11. doi: https://doi.org/ 10.1038/s41541-019-0132-6
Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines. 2021;9(3):221. doi: https://doi.org/ 10.3390/vaccines9030221
Kant A, Jansen J, Van Balveren L, Van Hunsel, F. Description of frequencies of reported adverse events following immunization among four different COVID-19 vaccine brands. Drug Saf. 2022;45(4):319-31. doi: https://doi.org/ 10.1007/s40264-022-01151-w
Paul E, Fancourt D. Predictors of uncertainty and unwillingness to receive the COVID-19 booster vaccine: An observational study of 22,139 fully vaccinated adults in the UK. Lancet Reg Health Eur. 2022;14. doi: https://doi.org/10.1016/j.lanepe.2022.100317
Antonelli M, Penfold R, Merino J, Sudre C, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43-55. doi: https://doi.org/10.1016/S1473-3099(21)00460-6
Kadali RA, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376-81. doi: https://doi.org/10.1016/j.ijid.2021.04.047
Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J Clin Med. 2021; 10(7):1428. doi: https://doi.org/ 10.3390/jcm10071428
Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219-26. doi: https://doi.org/10.1016/j.ijid.2021.08.013
Centers for Disease Control and Prevention. Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events [Internet]. 2020 [Cited 2022 Jun 26]. Avaiable from: https://www. cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html
Ramasamy MN, Minassian A, Ewer K, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020; 396(10267):1979-93. doi: https://doi.org/10.1016/S01406736(20)32466-1
Omeish H, Najdat A, Al-Azzam S, Tarabin N, Abu Hameed A, Al-Gallab N, et al. Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study. Hum Vaccin Immunother. 2022;18(1):1981086. doi: https:// doi.org/10.1080/21645515.2021.1981086
Zahid MN. Unfolding the Mild to Moderate Short-Term Side Effects of Four COVID-19 Vaccines Used in Bahrain: A Cross-Sectional Study. Vaccines. 2021;9(11):1369. doi: https:// doi.org/10.3390/vaccines9111369
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383:2603-15. doi: https://doi.org/10.1056/NEJMoa2034577.
Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. doi: https://doi.org/10.1016/S0140-6736(20)32661-1
Xia S, Zang Y, Wang Y, Wang H, Yang Y, Gao G, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39-51. doi: https:// doi.org/10.1016/S1473-3099(20) 30831-8
Menni C, Klaser K, Mayu A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939-49 doi: https://doi.org/10.1016/S1473-3099(21)00224-3
Wu Q, Dudley M, Chen X, Bai X, Dong K, Zhuang T, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021;19(1):1-16. doi: https://doi.org/10.1186/ s12916-021-02059-5
Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338-49. doi: https://doi.org/ 10.1016/S1473-3099(10)70049-9
Klein SL, Pekosz A. Sex-based biology and the rational design of influenza vaccination strategies. J Infect.Dis. 2014;209(suppl_3):S114-9. doi: https://doi.org/10.1093/infdis/jiu066